Adult lymphoblastic lymphoma

Craig A. Portell, John W. Sweetenham

Research output: Contribution to journalReview article

34 Citations (Scopus)

Abstract

Adult lymphoblastic lymphoma (LBL) is an aggressive form of non-Hodgkin lymphoma occurring in predominantly adolescent and young adult men. Lymphoblastic lymphoma is rare, accounting for 1% to 2% of all non-Hodgkin lymphomas and is of T-cell phenotype in 90% of cases. Lymphoblastic lymphoma is morphologically indistinct from acute lymphoblastic leukemia (ALL). Both express their lineage-specific markers as well as terminal deoxynucleotidyl transferase. The differences are often made on clinical grounds. Lymphoblastic lymphoma is characterized by a predominantly nodal distribution of disease, often with a large mediastinal mass. Patients with less than 25% bone marrow involvement have typically been categorized as LBL rather than ALL, although this has not been applied consistently in the literature. Gene expression studies have identified differences in gene expression, with LBL expressing higher levels of genes associated with cytoskeleton, adhesion, angiogenesis, and chemotaxis than ALL. Although LBL and ALL can be distinct clinically, chemotherapy strategies are often very similar. Acute lymphoblastic leukemia regimens, which incorporate intensive multidrug induction, consolidation, delayed intensification, and maintenance, have been shown to be superior to standard lymphoma regimens. As central nervous system (CNS) relapse is common, CNS prophylaxis with high-dose chemotherapy and intrathecal therapy is also standard. The prophylactic use of CNS irradiation has declined with the introduction of chemotherapy regimens incorporating high doses of CNS-penetrating drugs such as cytarabine and methotrexate. The use of consolidative radiation to the mediastinum remains uncertain. High-dose chemotherapy followed by autologous or allogeneic transplantation as consolidation for patients in CR1 is controversial with modern intensive chemotherapy regimens, although transplantation has a proven role in the relapse setting.

Original languageEnglish (US)
Pages (from-to)432-438
Number of pages7
JournalCancer Journal (United States)
Volume18
Issue number5
DOIs
StatePublished - Sep 1 2012
Externally publishedYes

Fingerprint

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Drug Therapy
Central Nervous System
Non-Hodgkin's Lymphoma
Central Nervous System Agents
Gene Expression
Recurrence
DNA Nucleotidylexotransferase
Autologous Transplantation
Cytarabine
Homologous Transplantation
Mediastinum
Chemotaxis
Cytoskeleton
Methotrexate
Young Adult
Lymphoma
Transplantation
Bone Marrow
Maintenance

Keywords

  • allogeneic stem cell transplant
  • autologous stem cell transplant
  • CNS prophylaxis
  • Lymphoblastic lymphoma
  • mediastinal irradiation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Adult lymphoblastic lymphoma. / Portell, Craig A.; Sweetenham, John W.

In: Cancer Journal (United States), Vol. 18, No. 5, 01.09.2012, p. 432-438.

Research output: Contribution to journalReview article

Portell, Craig A. ; Sweetenham, John W. / Adult lymphoblastic lymphoma. In: Cancer Journal (United States). 2012 ; Vol. 18, No. 5. pp. 432-438.
@article{3355b912a71b41cd9403953a9f827a4c,
title = "Adult lymphoblastic lymphoma",
abstract = "Adult lymphoblastic lymphoma (LBL) is an aggressive form of non-Hodgkin lymphoma occurring in predominantly adolescent and young adult men. Lymphoblastic lymphoma is rare, accounting for 1{\%} to 2{\%} of all non-Hodgkin lymphomas and is of T-cell phenotype in 90{\%} of cases. Lymphoblastic lymphoma is morphologically indistinct from acute lymphoblastic leukemia (ALL). Both express their lineage-specific markers as well as terminal deoxynucleotidyl transferase. The differences are often made on clinical grounds. Lymphoblastic lymphoma is characterized by a predominantly nodal distribution of disease, often with a large mediastinal mass. Patients with less than 25{\%} bone marrow involvement have typically been categorized as LBL rather than ALL, although this has not been applied consistently in the literature. Gene expression studies have identified differences in gene expression, with LBL expressing higher levels of genes associated with cytoskeleton, adhesion, angiogenesis, and chemotaxis than ALL. Although LBL and ALL can be distinct clinically, chemotherapy strategies are often very similar. Acute lymphoblastic leukemia regimens, which incorporate intensive multidrug induction, consolidation, delayed intensification, and maintenance, have been shown to be superior to standard lymphoma regimens. As central nervous system (CNS) relapse is common, CNS prophylaxis with high-dose chemotherapy and intrathecal therapy is also standard. The prophylactic use of CNS irradiation has declined with the introduction of chemotherapy regimens incorporating high doses of CNS-penetrating drugs such as cytarabine and methotrexate. The use of consolidative radiation to the mediastinum remains uncertain. High-dose chemotherapy followed by autologous or allogeneic transplantation as consolidation for patients in CR1 is controversial with modern intensive chemotherapy regimens, although transplantation has a proven role in the relapse setting.",
keywords = "allogeneic stem cell transplant, autologous stem cell transplant, CNS prophylaxis, Lymphoblastic lymphoma, mediastinal irradiation",
author = "Portell, {Craig A.} and Sweetenham, {John W.}",
year = "2012",
month = "9",
day = "1",
doi = "10.1097/PPO.0b013e31826b1232",
language = "English (US)",
volume = "18",
pages = "432--438",
journal = "Cancer Journal (United States)",
issn = "1528-9117",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Adult lymphoblastic lymphoma

AU - Portell, Craig A.

AU - Sweetenham, John W.

PY - 2012/9/1

Y1 - 2012/9/1

N2 - Adult lymphoblastic lymphoma (LBL) is an aggressive form of non-Hodgkin lymphoma occurring in predominantly adolescent and young adult men. Lymphoblastic lymphoma is rare, accounting for 1% to 2% of all non-Hodgkin lymphomas and is of T-cell phenotype in 90% of cases. Lymphoblastic lymphoma is morphologically indistinct from acute lymphoblastic leukemia (ALL). Both express their lineage-specific markers as well as terminal deoxynucleotidyl transferase. The differences are often made on clinical grounds. Lymphoblastic lymphoma is characterized by a predominantly nodal distribution of disease, often with a large mediastinal mass. Patients with less than 25% bone marrow involvement have typically been categorized as LBL rather than ALL, although this has not been applied consistently in the literature. Gene expression studies have identified differences in gene expression, with LBL expressing higher levels of genes associated with cytoskeleton, adhesion, angiogenesis, and chemotaxis than ALL. Although LBL and ALL can be distinct clinically, chemotherapy strategies are often very similar. Acute lymphoblastic leukemia regimens, which incorporate intensive multidrug induction, consolidation, delayed intensification, and maintenance, have been shown to be superior to standard lymphoma regimens. As central nervous system (CNS) relapse is common, CNS prophylaxis with high-dose chemotherapy and intrathecal therapy is also standard. The prophylactic use of CNS irradiation has declined with the introduction of chemotherapy regimens incorporating high doses of CNS-penetrating drugs such as cytarabine and methotrexate. The use of consolidative radiation to the mediastinum remains uncertain. High-dose chemotherapy followed by autologous or allogeneic transplantation as consolidation for patients in CR1 is controversial with modern intensive chemotherapy regimens, although transplantation has a proven role in the relapse setting.

AB - Adult lymphoblastic lymphoma (LBL) is an aggressive form of non-Hodgkin lymphoma occurring in predominantly adolescent and young adult men. Lymphoblastic lymphoma is rare, accounting for 1% to 2% of all non-Hodgkin lymphomas and is of T-cell phenotype in 90% of cases. Lymphoblastic lymphoma is morphologically indistinct from acute lymphoblastic leukemia (ALL). Both express their lineage-specific markers as well as terminal deoxynucleotidyl transferase. The differences are often made on clinical grounds. Lymphoblastic lymphoma is characterized by a predominantly nodal distribution of disease, often with a large mediastinal mass. Patients with less than 25% bone marrow involvement have typically been categorized as LBL rather than ALL, although this has not been applied consistently in the literature. Gene expression studies have identified differences in gene expression, with LBL expressing higher levels of genes associated with cytoskeleton, adhesion, angiogenesis, and chemotaxis than ALL. Although LBL and ALL can be distinct clinically, chemotherapy strategies are often very similar. Acute lymphoblastic leukemia regimens, which incorporate intensive multidrug induction, consolidation, delayed intensification, and maintenance, have been shown to be superior to standard lymphoma regimens. As central nervous system (CNS) relapse is common, CNS prophylaxis with high-dose chemotherapy and intrathecal therapy is also standard. The prophylactic use of CNS irradiation has declined with the introduction of chemotherapy regimens incorporating high doses of CNS-penetrating drugs such as cytarabine and methotrexate. The use of consolidative radiation to the mediastinum remains uncertain. High-dose chemotherapy followed by autologous or allogeneic transplantation as consolidation for patients in CR1 is controversial with modern intensive chemotherapy regimens, although transplantation has a proven role in the relapse setting.

KW - allogeneic stem cell transplant

KW - autologous stem cell transplant

KW - CNS prophylaxis

KW - Lymphoblastic lymphoma

KW - mediastinal irradiation

UR - http://www.scopus.com/inward/record.url?scp=84866944319&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866944319&partnerID=8YFLogxK

U2 - 10.1097/PPO.0b013e31826b1232

DO - 10.1097/PPO.0b013e31826b1232

M3 - Review article

C2 - 23006948

AN - SCOPUS:84866944319

VL - 18

SP - 432

EP - 438

JO - Cancer Journal (United States)

JF - Cancer Journal (United States)

SN - 1528-9117

IS - 5

ER -